Mounjaro is the first and only approved treatment in a different class of medication for type 2 diabetes.*
*It works differently than other type 2 diabetes medications by directly activating GIP and GLP-1 pathways to help regulate blood sugar.
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1.
What is Mounjaro?
Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.
See the results for type 2 diabetes
†In studies with or without other diabetes medications, the percentage of people taking Mounjaro who reached an A1C of less than 7% ranged from 75% (5 mg) to 90% (10 mg). People had an average starting A1C of 7.9% to 8.6% across the 5-mg, 10-mg, and 15-mg doses. A 40-week study was conducted to see if Mounjaro 5-mg, 10-mg, and 15-mg plus a basal insulin worked better than basal insulin alone. 90% of people taking Mounjaro 10-mg plus basal insulin achieved an A1C of under 7%.
Select Safety Information
Mounjaro can cause serious side effects, including:
Inflammation of your pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
Mounjaro is not a weight loss drug.
‡Individual results may vary. In studies with or without other diabetes medications, weight loss in adults ranged from 12 lb (5 mg) to 25 lb (15 mg).
Select Safety Information
Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including: swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
See how Mounjaro did in studies
 In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to Ozempic 1 mg in 1879 adults with type 2 diabetes who were also taking metformin and had a starting A1C of 8.3%. For people taking Mounjaro, their A1C was lowered on average by 2.0% on the 5-mg dose, 2.2% on the 10-mg dose, and 2.3% on the 15-mg dose. For people taking the Ozempic 1-mg dose, their A1C was lowered on average by 1.9%. |
 In a 52-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to titrated Tresiba, a basal insulin, in 1444 adults with type 2 diabetes who were also taking metformin with or without another oral diabetes medication. They had an average starting A1C of 8.1 to 8.2%. At the end of the study, 26% of people on Tresiba met the blood sugar goal (or target). The average daily dose of Tresiba was 49 units per day by the end of the study. For people taking Mounjaro, their A1C was lowered by 1.9% on the 5-mg dose, 2.0% on the 10-mg dose, and 2.1% on the 15-mg dose. For people taking Tresiba, their A1C was lowered by 1.3%. |
 In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to placebo in 475 adults with type 2 diabetes who were also taking insulin glargine. Some study participants were also taking metformin. They had a starting A1C of 8.2% to 8.4%. Select Safety Information Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness, and feeling jittery. For people taking Mounjaro and insulin glargine, their A1C was lowered by 2.1% on the 5-mg dose, 2.4% on the 10-mg dose, and 2.3% on the 15-mg dose. For people taking placebo and insulin glargine, their A1C was lowered by 0.9%. |
Select Safety Information
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
 In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to Ozempic 1 mg in 1879 adults with type 2 diabetes who were also taking metformin. They had an average baseline A1C of 8.3%. The difference between Mounjaro 5-mg and Ozempic 1-mg was not large enough to be considered meaningful. For people taking Mounjaro, 82% reached an A1C under 7% on the 5-mg dose, 86% reached an A1C under 7% on the 10-mg dose, and 86% reached an A1C under 7% on the 15-mg dose. For people taking Ozempic 1-mg, 79% reached an A1C under 7%. |
 In a 52-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to titrated Tresiba, a basal insulin, in 1444 adults with type 2 diabetes who were also taking metformin with or without another oral diabetes medication. They had an average starting A1C of 8.1% to 8.2%. At the end of the study, 26% of people on Tresiba met the blood sugar goal (or target). The average daily dose of Tresiba was 49 units per day by the end of the study. For people taking Mounjaro, 79% reached an A1C under 7% on the 5-mg dose, 82% reached an A1C under 7% on the 10-mg dose, and 83% reached an A1C under 7% on the 15-mg dose. For people taking Tresiba, 58% reached an A1C under 7%. |
 In a 40-week study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to placebo in 475 adults with type 2 diabetes who were also taking insulin glargine. Some study participants were also taking metformin. They had a starting A1C of 8.2% to 8.4%. Select Safety Information Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness, and feeling jittery. For people taking Mounjaro and insulin glargine, 87% reached an A1C under 7% on the 5-mg dose, 90% reached an A1C under 7% on the 10-mg dose, and 85% reached an A1C under 7% on the 15-mg dose. For people taking placebo and insulin glargine, 35% reached an A1C under 7%. |
Select Safety Information
Severe stomach problems. Stomach problems, sometimes severe, have been reported with Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
 *Mounjaro is not a weight loss drug. Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to Ozempic 1 mg. The average starting weight was between 204 to 209 pounds. People taking Mounjaro saw an average weight loss of 17 pounds on the 5-mg dose, 21 pounds on the 10-mg dose, and 25 pounds on the 15-mg dose. Those taking the Ozempic 1-mg dose saw an average weight loss of 13 pounds. |
 *Mounjaro is not a weight loss drug. Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to titrated Tresiba, a basal insulin commonly associated with weight gain. All participants also took metformin with or without another oral diabetes medication. The average starting weight was between 207 to 209 pounds. Those taking Mounjaro saw an average weight loss of 15 pounds on the 5-mg dose, 21 pounds on the 10-mg dose, and 25 pounds on the 15-mg dose. Those taking Tresiba saw an average weight gain of 4 pounds. |
| *Mounjaro is not a weight loss drug. Individual results may vary. In this study, the Mounjaro 5-mg, 10-mg, and 15-mg doses were compared to placebo. Study participants were also taking insulin glargine, a medication commonly associated with weight gain. Some study participants were also taking metformin. The average starting weight was between 208 to 212 pounds. Those taking Mounjaro plus insulin glargine saw an average weight loss of 12 pounds on the 5-mg dose, 17 pounds on the 10-mg dose, and 19 pounds on the 15-mg dose. Those taking insulin glargine and placebo gained an average of 4 pounds. |
Once-weekly Mounjaro is here to help you lower your A1C*
*Along with diet and exercise.
Talk to your doctor about Mounjaro at your next visit
What is Mounjaro?
Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.
Mounjaro helps your body both regulate blood sugar and decrease how much food you eat
Mounjaro is not a weight loss drug.
It may start working to lower blood sugar from the first dose
The 2.5 mg starting dose is not meant for blood sugar control.
Mounjaro works in multiple ways. It helps:
THE BODY RELEASE INSULIN WHEN BLOOD SUGAR IS HIGH
THE BODY REMOVE EXCESS SUGAR FROM THE BLOOD
STOP THE LIVER FROM MAKING AND RELEASING TOO MUCH SUGAR
REDUCE HOW MUCH FOOD IS EATEN
SLOW DOWN HOW QUICKLY FOOD LEAVES THE STOMACH. THIS LESSENS OVER TIME
You can learn about possible side effects of Mounjaro here.
Select Safety Information
Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.
Mounjaro Savings
We want to help. You may pay as little as $25 for a 1-month or 3-month prescription with the Mounjaro Savings Card.*
*For eligible commercially insured patients with Mounjaro coverage. Governmental beneficiaries excluded, terms and conditions apply.
*One month is defined as 28 days and 4 pens. Three months is defined as 84 days and up to 12 pens.
